Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26648662
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney
Disease Patients Receiving Kidney Transplants
#MMPMID26648662
Bakillah A
; Tedla F
; Ayoub I
; John D
; Norin AJ
; Hussain MM
; Brown C
Mediators Inflamm
2015[]; 2015
(?): 352356
PMID26648662
show ga
BACKGROUND: Functional abnormalities of high-density lipoprotein (HDL) could
contribute to cardiovascular disease in chronic kidney disease patients. We
measured a validated marker of HDL dysfunction, nitrated apolipoprotein A-I, in
kidney transplant recipients to test the hypothesis that a functioning kidney
transplant reduces serum nitrated apoA-I concentrations. METHODS: Concentrations
of nitrated apoA-I and apoB were measured using indirect sandwich ELISA assays on
sera collected from each transplant subject before transplantation and at 1, 3,
and 12 months after transplantation. Patients were excluded if they have history
of diabetes, treatment with lipid-lowering medications or HIV protease
inhibitors, prednisone dose > 15 mg/day, nephrotic range proteinuria, serum
creatinine > 1.5 mg/dL, or active inflammatory disease. Sera from 18 transplanted
patients were analyzed. Four subjects were excluded due to insufficient data.
Twelve and eight patients had creatinine < 1.5 mg/dL at 3 and 12 months after
transplantation, respectively. RESULTS. Nitrated apoA-I was significantly reduced
at 12 months after transplantation (p = 0.039). The decrease in apoA-I nitration
was associated with significant reduction in myeloperoxidase (MPO) activity (p =
0.047). In contrast to apoA-I, nitrated apoB was not affected after kidney
transplantation. CONCLUSIONS: Patients with well-functioning grafts had
significant reduction in nitrated apoA-I 12 months after kidney transplantation.
Further studies are needed in a large cohort to determine if nitrated apoA-I can
be used as a valuable marker for cardiovascular risk stratification in chronic
kidney disease.
free
free
free
